000009750 001__ 9750
000009750 005__ 20240124114330.0
000009750 0247_ $$2DOI$$a10.6083/g158bj21z
000009750 037__ $$aETD
000009750 245__ $$aBehavioral and molecular characterization of oxytocin's effect on alcohol consumption
000009750 260__ $$bOregon Health and Science University
000009750 269__ $$a2022
000009750 336__ $$aDissertation
000009750 502__ $$bPh.D.
000009750 520__ $$aDespite the prevalence and devastating impact of alcohol use disorder (AUD), treatment options remain inadequate with only three United States (U.S.) Food and Drug Administration (FDA) approved pharmacotherapies and limited efficacy across patient populations. Thus, development of new pharmacotherapies is necessary. Of crucial importance in designing such therapies are optimized preclinical, animal models for assessment of potential pharmacotherapies, including translationally relevant routes of administration and incorporation of the complex interactions of alcohol-related behaviors with the social environment. In this dissertation, I sought to further the translational relevance of the results by administering OXT intranasally, in line with human clinical trials. I aimed to characterize the behavioral mechanisms by recapitulating scenarios human patients face during medication-assisted maintenance of abstinence.
000009750 542__ $$fIn copyright - single owner
000009750 650__ $$aAlcoholism$$014412
000009750 650__ $$aOxytocin$$023453
000009750 6531_ $$apharmacotherapy
000009750 691__ $$aSchool of Medicine$$041369
000009750 692__ $$aDepartment of Behavioral Neuroscience$$041394
000009750 7001_ $$aPotretzke, Sheena
000009750 8564_ $$9c2705e29-7b65-4b0d-bfd6-7ad1e60482ff$$s4238379$$uhttps://digitalcollections.ohsu.edu/record/9750/files/Potretzke.Sheena.2022.pdf
000009750 905__ $$a/rest/prod/g1/58/bj/21/g158bj21z
000009750 909CO $$ooai:digitalcollections.ohsu.edu:9750$$pstudent-work
000009750 980__ $$aTheses and Dissertations